We selected anti-CD40 as a rational choice for combination with SBRT in the setting of pancreatic cancer due to previous activity of this agent in mouse models and human pancreatic cancer patients (21–23) and the potential for augmentation of T cell priming in combination with radiation (18, 25, 51). This evidence concerns the gene CD40 and pancreatic neoplasm.